News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe

Navigating Success During a Rare Disease Product Launch

January 18, 2024
By Herspiegel
News
Webcast

Webcasts

Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST

Join us to learn about current trends in rare disease drug development and commercialization, as well as implications for rare disease product launches. In this webcast, we share learnings from our 125+ pharmaceutical product launches, insights to identify risk and strategies to mitigate them, and best practices for launch timelines and stage gates.

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1651137&tp_key=395bcd3d64

Event Overview:

Rare disease products account for half of all US FDA approvals, most with fast-track designations, which means compressed launch timelines and increasingly competitive markets with smaller patient populations. Organizations need to start their project journey 24-36 months prior to approval to gain a comprehensive understanding of the patient journey, educate providers effectively, foster advocacy, and establish a clear path to diagnosis and access to treatment. Early alignment to a cross-functional strategy supports decisions about prioritizing and judiciously allocating limited resources pre-approval.

If you are developing assets for rare disease indications, take advantage of this presentation to learn how to ensure your launch is set up for success.

Key Learning Objectives:

  • Trends in rare disease drug development and commercialization
  • Unique considerations for major commercial decisions in rare disease markets
  • Identification of challenges and effective strategies to address them
  • Best practices for launch timelines and stage gates for Medical Affairs, Market Access, and Commercial perspectives

Who Should Attend:

  • CEOs, Chief Commercial Officers, Launch Leadership, Marketing Heads, EVPs of Marketing of organizations that are developing therapies for rare disease conditions.

Speakers:

Kapil Raina, MD
Principal, Market Access
Herspiegel

Brian Williams
SVP, Commercial Strategy and Execution
Herspiegel

Chris Zealey, MSc
Principal, Science and Strategy
Sixsense Strategy Group, a Herspiegel Company

Register Free: https://globalmeet.webcasts.com/starthere.jsp?ei=1651137&tp_key=395bcd3d64

Recent Videos
Lynlee Brown
Amy Hessels, Bayer
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Stock.adobe.com

Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry

Partha Anbil;Kamini Anbil
May 15th 2025
Article

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.


Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.


GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

Don Tracy, Associate Editor
May 13th 2025
Article

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.


The Three Pillars of Pharma’s New Commercial Model

The Three Pillars of Pharma’s New Commercial Model

Saby Mitra
May 12th 2025
Article

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

Related Content

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Regeneron Acquires 23andMe for $256 Million in Bankruptcy Deal

Don Tracy, Associate Editor
May 19th 2025
Article

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Stock.adobe.com

Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry

Partha Anbil;Kamini Anbil
May 15th 2025
Article

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.


Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.


GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024, ASHP Reports

Don Tracy, Associate Editor
May 13th 2025
Article

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society of Health-System Pharmacists, who warns of tariff-driven supply chain threats and continued growth in clinic drug costs.


The Three Pillars of Pharma’s New Commercial Model

The Three Pillars of Pharma’s New Commercial Model

Saby Mitra
May 12th 2025
Article

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.